Skip Ribbon Commands
Skip to main content

Direct Oral Anticoagulants (DOACs) at Its Adolescence – Has It Come of Age?

It is now close to a decade since the first DOAC, dabigatran, was introduced to our shores for the prophylaxis and treatment of thrombotic disorders. This direct thrombin inhibitor (DTI) was later joined by two anti-Xa inhibitors, rivaroxaban and apixaban. DOACs have since drastically altered the anticoagulation landscape with expanded indications and wider acceptance by both clinicians and patients.

This lecture will discuss the progress of DOACs in the past decade in respect to its indications and safety and explore its future potential for both traditional and expanded indications as it continues to displace the classic anticoagulants in reducing thrombotic events.

Click here for more lecture details.

Lecture Details

22 January 2020, Wednesday

6.30 pm - 7.30 pm

1 hour


Registration Closing Date:
8 January 2020, Wednesday

Learning Space Room 4/5 
Singapore General Hospital 
Block 6 Level 1 
Outram Road
Singapore 169608